Potential roles for endothelins in systemic inflammatory response syndrome with a particular relationship to cytokines

被引:83
作者
Battistini, B
Forget, MA
Laight, D
机构
[1] UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,WILLIAM HARVEY RES INST,LONDON EC1M 6BQ,ENGLAND
[2] INST NATL RECH SCI SANTE,MONTREAL,PQ H9R 1G6,CANADA
来源
SHOCK | 1996年 / 5卷 / 03期
关键词
D O I
10.1097/00024382-199603000-00002
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Endothelins (ETs) are multifunctional isopeptides and their role in several pathophysiologies is slowly emerging. They are possible therapeutic targets in sepsis and other systemic inflammatory response syndromes (SIRS). In such conditions, elevated concentrations of ETs have been reported, together with other proinflammatory markers such as several cytokines. Some of the cytokines even modulate the expression, production, and release of ETs from cells and also the biological responsiveness of ETs into the circulation. Here, we systematically review the literature and discuss the role of these peptides in affecting vascular and inflammatory responses in SIRS. This review also intends to provide a better understanding of the mechanisms of ETs and their interrelationships to other mediators, mainly cytokines, in SIRS. There is no doubt that ETs are useful markers of Vascular injury in SIRS. From experimental evidence in animals, endothelins, as potent vasoconstrictors, play a beneficial central compensatory role against the loss of vascular tone associated with SIRS. Conversely, endothelins compromise the circulation in several vascular beds and exacerbate conditions in which inadequate perfusion already exists during the early stages of SIRS. Since no single magic solution has been found for complex diseases related to SIRS, we should look toward a group of mediators, such as cytokines and endothelins, acting as team players.
引用
收藏
页码:167 / 183
页数:17
相关论文
共 182 条
[1]  
ACHMAD TH, 1992, BIOCHEM BIOPH RES CO, V189, P994
[2]  
AGUI T, 1994, BLOOD, V84, P2531
[3]  
ANDERSEN BM, 1980, ACTA PATH MICRO IM B, V88, P231
[4]  
ANGGARD E, 1989, J CARDIOVASC PHARM, V13, pS46
[5]  
ARAMORI I, 1992, J BIOL CHEM, V267, P12468
[6]  
AUGUET M, 1990, ARCH MAL COEUR VAISS, V83, P1187
[7]  
AYALA J, 1990, CYTOKINE, V2, P121
[8]  
AYALA J, 1961, CYTOKINE, V2, P170
[9]  
AYALA J, 1991, CYTOKINE, V2, P170
[10]   SEPSIS-ASSOCIATED RENAL VASOCONSTRICTION - POTENTIAL TARGETS FOR FUTURE THERAPY [J].
BADR, KF .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 20 (03) :207-213